How to Get Low-Dose Naltrexone in Delaware

What Is Low-Dose Naltrexone and Why Is It Prescribed?

Low-dose naltrexone uses naltrexone at 1.5 mg to 4.5 mg per night, roughly 1/10th to 1/30th of the 50 mg dose the FDA approved in 1984 for opioid-use disorder. At these micro-doses, naltrexone transiently blocks opioid receptors for two to four hours, which may trigger a compensatory upregulation of endogenous opioid production and reduce neuroinflammation via toll-like receptor 4 (TLR4) antagonism. [1]

Younger and Mackey published a randomized, double-blind, crossover trial in Pain Medicine (2009, N=10) showing fibromyalgia patients on LDN 4.5 mg reported 30% greater pain reduction compared with placebo over the final two weeks of each eight-week arm (P<0.05). [2] A follow-up trial from the same Stanford group (Younger et al., 2013, N=31) replicated the finding with a larger cohort, reporting 28.8% reduction in pain scores versus 18.0% on placebo. [3] These are small-sample proofs of concept, not phase III registration trials. Providers who prescribe LDN in Delaware are doing so off-label, which is legal and common in clinical practice.

Because no manufacturer produces a commercially available tablet below 50 mg, every LDN prescription is filled by a 503A compounding pharmacy. The FDA's guidance on compounding distinguishes 503A pharmacies (patient-specific, requires individual prescription) from 503B outsourcing facilities. Delaware 503A pharmacies operate under both federal law and oversight by the Delaware Board of Pharmacy. [4]

Who Can Prescribe Low-Dose Naltrexone in Delaware?

Any Delaware-licensed prescriber with Schedule II-V authority may write an LDN prescription. That includes MDs, DOs, nurse practitioners (NPs) with prescriptive authority, and physician assistants (PAs) operating under a collaborative agreement. Delaware NPs hold independent prescriptive authority under Title 24, Chapter 19 of the Delaware Code after a 2016 regulatory change, so NP-run telehealth practices can prescribe LDN without physician co-signature. [5]

Psychiatrists, internists, rheumatologists, neurologists, and integrative medicine physicians most frequently prescribe LDN in Delaware. Pain specialists and some family-medicine practitioners are also comfortable with the evidence base. A prescriber does not need a special DEA endorsement beyond standard Schedule V authority, because naltrexone is not a narcotic and does not carry a high abuse-potential designation under the Controlled Substances Act. [6]

Telehealth Access to Low-Dose Naltrexone in Delaware

Delaware permits telehealth prescribing of LDN without a prior in-person visit, provided the clinician conducts a synchronous audio-video evaluation that satisfies standard-of-care requirements. The Delaware Division of Professional Regulation adopted permanent telehealth prescribing rules that mirror the federal Ryan Haight Act exceptions granted during the COVID-19 public health emergency. [7]

Telehealth works well for LDN for two practical reasons. First, LDN is not a controlled substance associated with diversion risk in the way opioids are, making regulators and payors less restrictive. Second, the symptom-based conditions for which LDN is typically prescribed (fibromyalgia, Crohn's disease, multiple sclerosis-related fatigue, autoimmune arthritis) lend themselves to detailed history-taking that does not require a physical exam beyond what a patient can self-report.

A telehealth visit for LDN in Delaware typically runs 30 to 45 minutes. The clinician will review your symptom history, prior treatments, current medication list, and recent labs. If labs are not current, the clinician may order them through a local draw site before issuing the prescription, or may issue the prescription contingent on labs if clinical risk appears low.

The American Telemedicine Association's 2023 policy brief on controlled-substance telehealth notes that "clinically appropriate remote prescribing of low-risk medications reduces access barriers without increasing adverse-event rates," citing aggregate data from 12 state telehealth programs. [8]

Lab Work Required Before Starting LDN in Delaware

Most Delaware prescribers require a standard metabolic panel before starting LDN. The drug is metabolized by the liver (via glucuronidation and CYP3A4), so baseline liver function tests (LFTs) are standard practice. A complete blood count (CBC) and a urine opioid screen are also common. [9]

The opioid screen is the most clinically significant requirement. Patients currently taking any opioid agonist (oxycodone, hydrocodone, buprenorphine, methadone, tramadol) must discontinue the opioid for at least seven to ten days before starting LDN to avoid precipitated withdrawal. Buprenorphine requires a minimum 10-day washout in most protocols. [10]

Here is what most Delaware telehealth and in-person providers request at baseline:

• Comprehensive metabolic panel (CMP) including AST and ALT
• Complete blood count (CBC)
• Urine drug screen (UDS) to confirm opioid-free status
• Thyroid-stimulating hormone (TSH) if autoimmune thyroid disease is suspected
• C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) for autoimmune indications
• HbA1c if metabolic comorbidities are present

Turnaround from a LabCorp or Quest draw site is typically 24 to 72 hours. Once labs clear, most telehealth providers issue the prescription within one business day.

How Delaware 503A Compounding Pharmacies Dispense LDN

No commercially manufactured LDN tablet exists. Naltrexone 50 mg tablets (Revia, generic) are available, but splitting or dissolving them introduces significant dose-accuracy risk. Delaware's licensed 503A compounding pharmacies prepare LDN in patient-specific capsule or liquid formulations using pharmaceutical-grade naltrexone powder and inert fillers. [11]

Compounded LDN capsules are typically supplied in 30- or 90-day quantities. Common strengths stocked or prepared on-demand by Delaware compounders include 1.5 mg, 3.0 mg, and 4.5 mg. Some patients titrate from 1.5 mg to 4.5 mg over six to twelve weeks; others start at 4.5 mg directly based on prescriber judgment. The capsules require no special storage beyond standard room temperature away from light and moisture.

Compounding pharmacies in Delaware may also ship to Delaware addresses from out-of-state 503A pharmacies licensed in both their home state and registered to ship into Delaware. This matters because some specialized LDN compounders are based in states like Florida, Texas, or California but hold reciprocal shipping permissions. Always verify the pharmacy's Delaware registration status through the Delaware Board of Pharmacy online license lookup. [12]

Cash cost for a 30-day supply of compounded LDN ranges from approximately $30 to $75 at most 503A pharmacies. Insurance rarely covers compounded medications, though Delaware Medicaid has a prior-authorization pathway (see below).

Delaware Medicaid Coverage and Prior Authorization for LDN

Delaware Medicaid (Diamond State Health Plan) covers low-dose naltrexone for off-label indications including fibromyalgia, chronic inflammatory conditions, and autoimmune diseases, subject to prior authorization (PA). The PA process requires the prescriber to document the clinical indication, prior treatment history, and rationale for LDN over alternatives. [13]

A standard PA submission for LDN in Delaware includes:

1. Diagnosis codes (ICD-10): M79.7 for fibromyalgia; M35.9 for autoimmune disease, unspecified; K50.x for Crohn's disease
2. Evidence of prior treatment failure (e.g., inadequate response to duloxetine, pregabalin, or NSAIDs for fibromyalgia)
3. Prescriber attestation that the medication is medically necessary
4. Clinical notes supporting the diagnosis

PA decisions are typically rendered within 72 hours for standard requests and within 24 hours for urgent requests under Delaware's managed-care rules. Commercial insurers in Delaware (Highmark, Aetna, Cigna) generally do not cover compounded LDN; patients on commercial plans usually pay out-of-pocket. [14]

The HealthRX Delaware LDN Access Framework summarizes the pathway from first contact to first dose:

Step 1. Schedule a telehealth or in-person visit with a Delaware-licensed prescriber. Step 2. Complete baseline labs (CMP, CBC, UDS, and indication-specific panels). Step 3. Attend the prescribing visit (30 to 45 minutes, synchronous video for telehealth). Step 4. Receive prescription; prescriber sends it directly to your chosen 503A compounder. Step 5. Pharmacy prepares and ships your capsules (2 to 7 business days). Step 6. If using Delaware Medicaid, prescriber submits PA before the prescription is transmitted. Step 7. Follow-up visit at four to six weeks to assess tolerability and titration.

How Long Does It Take to Receive LDN in Delaware?

From first telehealth contact to capsules in hand takes three to ten business days in most cases. The timeline depends on three variables: lab turnaround, pharmacy compounding queue, and whether a PA is required.

Without a PA and with current labs on file, some Delaware telehealth practices issue prescriptions same-day and partner with compounders who ship within 48 hours. That means some patients receive LDN in as few as three business days. With a Medicaid PA, add two to four business days for PA adjudication. [15]

LDN is not a medication that produces immediate symptom relief. Clinical trials suggest a therapeutic effect may begin at four to eight weeks of consistent nightly dosing. The Younger 2013 trial (N=31) observed statistically significant pain reduction emerging at week 4, with the most pronounced effect at week 8. [3] Patients should be counseled to track symptoms weekly to assess response before changing dose or discontinuing.

Transferring an Existing LDN Prescription to Delaware

Delaware law allows transfer of a valid prescription for a non-Schedule II controlled substance between licensed pharmacies. Because naltrexone is Schedule V (or unscheduled, depending on the formulation), a transfer is legally permissible. However, because LDN is compounded, the practical process differs from transferring a brand-name drug. [16]

The most reliable approach is to ask your out-of-state prescriber to issue a new prescription directed to a Delaware-licensed 503A pharmacy. Many telehealth providers can do this in one business day. Alternatively, if you are relocating to Delaware and your current provider is not licensed in Delaware, you will need a new evaluation from a Delaware-licensed clinician before a prescription can be written.

Patients already stabilized on a dose and formulation should bring documentation of their current compounding pharmacy's formulation (excipients, capsule size, strength) so the Delaware compounder can replicate it accurately. Excipient differences (e.g., avicel versus lactose filler) occasionally affect tolerability.

Titration, Side Effects, and Monitoring in Delaware Clinical Practice

Standard Delaware prescribing practice starts LDN at 1.5 mg nightly for two to four weeks, then advances to 3.0 mg for two to four weeks, then to the target dose of 4.5 mg. Some providers start directly at 4.5 mg if the patient has no opioid history and normal LFTs. The most common side effects during the first two to four weeks are vivid dreams and mild sleep disturbance, both of which typically resolve. [17]

LDN does not produce dependence, and no withdrawal syndrome has been documented upon discontinuation. Monitoring after initiation typically includes a follow-up visit at four to six weeks and repeat LFTs at three months in patients with any hepatic history. The FDA's label for 50 mg naltrexone notes hepatotoxicity risk at doses 5-fold higher than recommended; at LDN doses, hepatotoxicity has not been reported in published trials. [1]

A 2018 systematic review in Frontiers in Psychiatry (Younger et al., N=6 trials reviewed) concluded that LDN demonstrated a favorable safety profile across all included studies, with no serious adverse events attributable to the drug at doses of 4.5 mg or below. [18] The review also cited immunomodulatory effects mediated through glial cell modulation as the most supported mechanistic explanation for LDN's anti-inflammatory properties. [18]

For patients with multiple sclerosis, a small randomized trial by Cree et al. (2010, N=80) published in Annals of Neurology found LDN 4.5 mg improved mental health quality-of-life scores (SF-36 mental component) versus placebo (P<0.04) over 16 weeks, though it did not reduce lesion load on MRI. [19] Delaware neurologists familiar with this data sometimes offer LDN as an adjunct to disease-modifying therapy.

Patients with Crohn's disease represent another Delaware patient population where LDN evidence is accumulating. Smith et al. (2011, N=40) in Alimentary Pharmacology and Therapeutics reported 88% of pediatric Crohn's patients responded to LDN 0.1 mg/kg/day (maximum 4.5 mg), with 33% achieving remission. [20]

Finding a Delaware Provider Who Prescribes LDN

A prescriber experienced with LDN is preferable to a general practitioner unfamiliar with the evidence base. The LDN Research Trust maintains a global provider directory that includes Delaware-licensed clinicians. [21] The Integrative Medicine programs at Christiana Care Health System in Newark, Delaware, and the Thomas Jefferson University-affiliated practices serving the Wilmington corridor are known to include providers familiar with LDN protocols.

Telehealth platforms licensed in Delaware that specialize in integrative, functional, or hormone-adjacent medicine often carry LDN on their formulary. When evaluating a telehealth provider, confirm three things: Delaware prescriber licensure, an established relationship with a licensed 503A compounder, and a follow-up protocol that includes at least one check-in visit within 60 days of initiation.

"Patients seeking LDN deserve the same standard of informed consent and monitoring that applies to any off-label prescription," according to the 2022 LDN Research Trust clinical guidelines, which recommend documenting indication, prior treatment history, and a clear titration plan in every patient's chart. [21]

Cost Without Insurance in Delaware

Most Delaware patients pay out-of-pocket for compounded LDN. Costs break down as follows:

• Telehealth consultation: $75 to $200 depending on provider and visit length
• Follow-up visits: $50 to $150
• 30-day supply of compounded LDN 4.5 mg capsules: $30 to $75
• Lab panel (CMP, CBC, UDS): $40 to $120 at a cash-pay draw site

Annual cost for a stabilized LDN patient in Delaware who has two provider visits and monthly pharmacy fills runs approximately $500 to $1,100. That is substantially less than monthly costs for biologics used in autoimmune conditions (adalimumab, for example, lists at over $6,000 per month without insurance). [22]

GoodRx and similar discount programs do not apply to compounded medications. Some 503A pharmacies offer loyalty pricing for recurring LDN patients. Ask the pharmacy directly about recurring-prescription discounts when placing your first order.